|
MOSPD2 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.98230321046822E-12 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
2.07470041146962E-10 |
| Normal-vs-Stage2 |
1.75524999999066E-05 |
| Normal-vs-Stage3 |
6.4144245470743E-12 |
| Normal-vs-Stage4 |
7.70006280959024E-12 |
| Stage1-vs-Stage2 |
6.923000E-01 |
| Stage1-vs-Stage3 |
8.548300E-02 |
| Stage1-vs-Stage4 |
8.002000E-03 |
| Stage2-vs-Stage3 |
1.239230E-01 |
| Stage2-vs-Stage4 |
3.334300E-02 |
| Stage3-vs-Stage4 |
3.863600E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
6.77236045021345E-15 |
| Normal-vs-AfricanAmerican |
1.394670E-04 |
| Normal-vs-Asian |
4.63049999999132E-06 |
| Caucasian-vs-AfricanAmerican |
3.853200E-01 |
| Caucasian-vs-Asian |
1.115030E-01 |
| AfricanAmerican-vs-Asian |
7.819800E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
8.903999759724E-11 |
| Normal-vs-Female |
4.05508959744338E-12 |
| Male-vs-Female |
3.715600E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
9.22770004851969E-09 |
| Normal-vs-Age(41-60Yrs) |
1.51479939702881E-11 |
| Normal-vs-Age(61-80Yrs) |
3.44799744311786E-11 |
| Normal-vs-Age(81-100Yrs) |
9.65859999999541E-05 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
2.702000E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
1.775830E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
1.711200E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
6.632600E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
2.799000E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
3.231800E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
7.068200E-02 |
| Classical-VS-Follicular |
1.927620E-01 |
| Classical-VS-Other |
4.326400E-01 |
| Classical-VS-Normal |
2.38764563675886E-12 |
| Tall-VS-Follicular |
1.746270E-02 |
| Tall-VS-Other |
9.451800E-01 |
| Tall-VS-Normal |
5.24320031836112E-10 |
| Follicular-VS-Other |
3.168400E-01 |
| Follicular-VS-Normal |
3.67860000000109E-05 |
| Other-VS-Normal |
1.558020E-03 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
5.14440001708749E-09 |
| Normal-vs-N1 |
1.35540467738338E-11 |
| N0-vs-N1 |
1.336150E-02 |
|
|
